24 hour contact: 01707 666297
The RVC Equine Referral Hospital is the only centre in the UK to offer melanoma treatment for horses using non-invasive heat technology
The Royal Veterinary College (RVC) Equine Referral Hospital has become the first clinic in the UK to offer a new melanoma treatment for horses, specially targeted at lesions that are not able to be surgically removed. This will improve the way in which we are able to treat horses with melanoma, resulting in a better quality of life for those affected by the disease.
Melanoma is a very common nodular skin disease that affects older grey horses of any breed or gender. It is estimated that more than 80 per cent of grey horses will have at least one melanoma during their lifetime.
This new treatment specifically focuses on melanomas affecting the parotid region (salivary glands behind the jaw bones) and other anatomically sensitive areas that are less amenable to surgery. Until now, there has been no effective treatment option for lesions in these areas.
The RVC Equine Referral Hospital is welcoming eligible horses to undertake the treatment, which involves thermofield hyperthermia and intratumoral chemotherapy. Thermofield hyperthermia transfers a large volume of electromagnetic energy deep into biological tissue. The absorbed energy then causes molecular friction, gently heating the targeted area to therapeutic temperatures that selectively kills cancerous cells without harming the surrounding healthy tissue. In addition, the heat increases drug penetration into tumours and inhibits DNA repair in cancer cells. The equipment is safe, effective, and easy to use.
The RVC Animal Care Trust have funded this specialist equipment needed to facilitate this treatment. Horses that meet the criteria will receive three treatments, one week apart. This involves injection of the chemotherapeutic drug into the melanoma, under sedation, followed by hyperthermia using the thermofield unit. The entire procedure takes approximately one hour to complete and is relatively painless for the horse. A second hyperthermia treatment is then performed the following day, before the horse is discharged. The whole process is repeated for a total of three treatment rounds.
Dr Michael Hewetson, Senior Lecturer in Equine Medicine at the RVC said:
“Although thermofield hyperthermia combined with intratumoral chemotherapy is a relatively new treatment, I have been impressed with the response in the horses that we have treated thus far, and I am optimistic for the future. We will be collecting data over the coming months to report on its effectiveness.”
This treatment will only be available in the RVC’s Equine Referral Hospital and horses will need to be admitted to the hospital for assessment and treatment. For more information, please visit https://rvc.uk.com/equine-thermofield and for case referrals, please contact firstname.lastname@example.org or 01707 666297.
Notes to Editors
For media enquiries, please contact:
About the RVC
- The Royal Veterinary College (RVC) is the UK's largest and longest established independent veterinary school and is a Member Institution of the University of London.
- It is one of the few veterinary schools in the world that hold accreditations from the RCVS in the UK (with reciprocal recognition from the AVBC for Australasia, the VCI for Ireland and the SAVC for South Africa), the EAEVE in the EU, and the AVMA in the USA and Canada.
- The RVC is ranked as the top veterinary school in the world in line with the QS World University Rankings by subject, 2021.
- The RVC offers undergraduate and postgraduate programmes in veterinary medicine, veterinary nursing and biological sciences.
- In 2017, the RVC received a Gold award from the Teaching Excellence Framework (TEF) – the highest rating a university can receive.
- A research led institution with 79% of its research rated as internationally excellent or world class in the Research Excellence Framework 2014.
- The RVC provides animal owners and the veterinary profession with access to expert veterinary care and advice through its teaching hospitals and first opinion practices in London and Hertfordshire.